advanced solid tumors
Conditions
Interventions
case series:Recombinant human adenovirus type 5 combined with PD-1 injection
Sponsors
Fuzhou First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years (including the boundary value), no gender limit. 2. Patients with confirmed advanced solid tumors, advanced solid tumors that have failed standard treatment or lack of effective treatment. 3. Patients or their legal representatives understand and sign the informed consent form. 4. At least one lesion that can be safely injected intratumorally with oncolytic adenovirus as the target lesion, with a diameter of >=1cm on spiral CT or >=2cm on ordinary CT, and can be measured by imaging. 5. The ECOG score is 0-2.
Exclusion criteria
Exclusion criteria: 1. Physicians participating in the disease registration study believe that patients may not be able to provide continuous follow-up information. 2. Any uncontrollable clinical problems (such as severe psychiatric, neurological, cardiovascular, respiratory or other systemic disease). 3. Contraindications of related drugs (such as oncolytic adenovirus, PD-1 inhibitor, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate(ORR);Disease Control Rate(DCR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival(PFS);Overall Survival(OS); | — |
Countries
China
Contacts
Public ContactXie Fangwei
Fuzhou First Hospital
Outcome results
None listed